Mesothelioma

The Halpern Law Firm Would Like to Welcome Two New Attorneys to the Firm

Retrieved on: 
Wednesday, November 8, 2023
Bar examination, Bar, Multistate Professional Responsibility Examination, Temple University Beasley School of Law, Law, Lawyer, University of Pittsburgh School of Law, Rest, Asbestos-related diseases, Mesothelioma, University, Wilfrid Sellars, Performance test (bar exam), Nursing, Real estate

PHILADELPHIA and PITTSBURGH, Nov. 8, 2023 /PRNewswire/ -- The Halpern Law Firm would like to welcome two new attorneys to the firm: Daniel Liberio and Thaddeus Kotarski. Daniel attended Temple University's James E. Beasley School of Law and will be working out of the Philadelphia office, while Thad attended The University of Pittsburgh School of Law and will be working out of the Pittsburgh office. The Halpern Law Firm believes that both Daniel and Thad will make great additions to this growing firm.

Key Points: 
  • PHILADELPHIA and PITTSBURGH, Nov. 8, 2023 /PRNewswire/ -- The Halpern Law Firm would like to welcome two new attorneys to the firm: Daniel Liberio and Thaddeus Kotarski.
  • The Halpern Law Firm believes that both Daniel and Thad will make great additions to this growing firm.
  • David Halpern, founder of the Halpern law Firm, is immensely proud of the two newest members of the group of attorneys.
  • The Halpern Law Firm has offices throughout the state of Pennsylvania, including Johnstown, Pittsburgh, Scranton, Philadelphia, and Allentown and can be contacted at any time at (800) 505–6000.

Molecular Templates Announces First Patient Dosed in Phase 1 Trial Evaluating MT-8421, a Novel Engineered Toxin Body Targeting CTLA-4, in Advanced Solid Tumors

Retrieved on: 
Thursday, November 2, 2023
Neoplasm, HCC, NSCLC, PD, Renal cell carcinoma, Therapy, Cancer, ESCC, SCCHN, Head, MSI-H, RCC, Pharmacokinetics, Mesothelioma, Lung cancer, Melanoma, Safety, Hepatocellular carcinoma, TME, Patient, Carcinoma, Neck, Pharmaceutical industry

AUSTIN, Texas, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating MT-8421, a novel engineered toxin body targeting CTLA-4, for the treatment of advanced solid tumors.

Key Points: 
  • AUSTIN, Texas, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Molecular Templates, Inc. (Nasdaq: MTEM, “Molecular Templates,” or “MTEM”), a clinical-stage biopharmaceutical company developing novel therapeutics for oncology with potent differentiated mechanisms of action, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating MT-8421, a novel engineered toxin body targeting CTLA-4, for the treatment of advanced solid tumors.
  • The Phase 1 study is a multi-center open-label, dose-escalation, dose-expansion, and a first-in-human study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and the preliminary efficacy of MT-8421.
  • Approximately 24-30 patients are anticipated to enroll in Part A dose escalation with a starting dose of 32 mcg/kg.
  • “We look forward to this approach providing patient benefit in this first-in-human study.”

ProfoundBio Presents Promising Data on ADC Programs, Including Early Clinical Results of Rinatabart Sesutecan in Ovarian and Endometrial Cancers, at SITC 2023

Retrieved on: 
Friday, November 3, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, CR, Rat, Neoplasm, Patient, Pneumonitis, Ovarian cancer, PDT, Trae tha Truth, MPH, Therapy, Endometrial cancer, Pharmacokinetics, Safety, Conjugation, PTK7, MMAE, SITC, Immunotherapy, SD, Bone marrow, ADC, Spacecraft, Breast cancer, Mesothelioma, Lung cancer, Society, Cancer, Cytopenia, Therapeutic index, Fatigue, Fine chemical, Medical imaging, Vaccine, Pharmaceutical industry, Communications satellite, Part

ProfoundBio , a clinical-stage biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for cancer, today announced multiple data presentations at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023).

Key Points: 
  • ProfoundBio , a clinical-stage biotechnology company developing novel antibody-drug conjugate (ADC) therapeutics for cancer, today announced multiple data presentations at the Society for Immunotherapy of Cancer’s 38th Annual Meeting (SITC 2023).
  • “We are thrilled to present proof-of-concept data from our novel sesutecan ADC platform with the initial clinical results for Rina-S,” said ProfoundBio Chief Medical Officer Naomi Hunder, M.D.
  • Enrolled patients had the following tumor types: ovarian cancer (n=17), endometrial cancer (n=9), breast cancer (n=3), non-small cell lung cancer (n=5), and mesothelioma (n=2).
  • Superior tumor growth inhibition and tolerability relative to the precedent PTK7-directed ADC cofetuzumab pelidotin were observed in head-to-head preclinical studies.

A2 Bio Presents Oral and Poster Presentations Highlighting BASECAMP-1 and EVEREST-1 Patient Screening at 2023 Society for Immunotherapy of Cancer (SITC) Annual Meeting

Retrieved on: 
Thursday, November 2, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Tempus, Neoplasm, Patient, CAR, Society for Immunotherapy of Cancer, MSLN, Carcinoembryonic antigen, Cell, NYU, SITC, Immunotherapy, Lung, NGS, CEA, Medicine, AWARE, Annual general meeting, Mesothelioma, HLA, Pharmaceutical industry, Medical imaging, Vaccine, A2

Additionally, A2 Bio is presenting two posters on November 4, 2023, detailing the BASECAMP-1 master pre-screening trial and EVEREST-1 CAR T interventional trial.

Key Points: 
  • Additionally, A2 Bio is presenting two posters on November 4, 2023, detailing the BASECAMP-1 master pre-screening trial and EVEREST-1 CAR T interventional trial.
  • “BASECAMP-1 provides patients an early opportunity to be identified and triaged to the appropriate EVEREST logic-gate Tmod™ CAR T trial.
  • A2 Bio has partnered with Tempus, a leader in precision medicine, to bring the latest technology to patient screening.
  • Details of the presentations are below:
    The two posters will be available on the A2 Bio website after November 4, 2023.

Key Lawyer in Johnson & Johnson Talc Litigation Supports Call to Rethink Legal Strategies in Light of Failure of Texas Two-Step

Retrieved on: 
Thursday, November 2, 2023
General Health, Other Retail, Professional Services, Business, Oncology, Consumer, Cosmetics, Retail, Legal, Women, Finance, Health, Legacy, NYSE, Ovarian cancer, Sidley Austin, Bloomberg Law, JNJ, LTL, Lawyer, Bankruptcy, Mesothelioma, Woman, Johnson & Johnson, Sidley, Insurance

In the commentary, Mr. Conlan rightfully points out that the Texas Two-Step bankruptcy approach, employed by several solvent and highly profitable mass tort defendants, has yielded a series of high-profile failures.

Key Points: 
  • In the commentary, Mr. Conlan rightfully points out that the Texas Two-Step bankruptcy approach, employed by several solvent and highly profitable mass tort defendants, has yielded a series of high-profile failures.
  • In a Texas Two-Step, an otherwise profitable company moves some or all its liabilities into another company and then places the second company into bankruptcy.
  • This strategy includes two recent bankruptcy attempts involving LTL (Johnson & Johnson) which federal courts found were filed in bad faith.
  • Legacy is able to advise and acquire restructured liability-tainted companies and manage the liabilities over several decades to finality.

European Medicines Agency Validates Bristol Myers Squibb’s Application for Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy for the First-Line Treatment of Adult Patients with Unresectable or Metastatic Urothelial Carcinoma

Retrieved on: 
Monday, October 30, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Survival, BMY, Bristol Myers Squibb, NYSE, ESMO, Clinical Genitourinary Cancer, Progression-free survival, Cancer, Congress, Mesothelioma, PFS, European Society for Medical Oncology, European Medicines Agency, EMA, Metastasis, Lung cancer, Checkmate, Safety, Patient, OS, Carcinoma, Pharmaceutical industry, Nivolumab

Validation of the application confirms the submission is complete and begins the EMA’s centralized review procedure.

Key Points: 
  • Validation of the application confirms the submission is complete and begins the EMA’s centralized review procedure.
  • “We know that approximately 20% to 25% of patients diagnosed with urothelial carcinoma will experience disease metastasis, and an additional 5% of patients present de novo with metastatic disease.
  • The OS and PFS data from CheckMate -901 were presented at the European Society for Medical Oncology (ESMO) Congress 2023 .
  • Bristol Myers Squibb thanks the patients and investigators involved in the CheckMate -901 clinical trial.

Simon Greenstone Panatier Earns Law Firm of the Year Recognition

Retrieved on: 
Thursday, October 26, 2023
Community Foundation of the Eastern Shore, PC, Greatest hits album, North Texas Food Bank, History, Renaissance Tower (Dallas), Workplace, Simon Greenstone Panatier, Frank Andrews (Texas lawyer), Justice, Administered prices, Trailblazer, Student, Asbestos, Catastrophic injury, Mesothelioma, Public, Cancer, Nursing

DALLAS, Oct. 26, 2023 /PRNewswire/ -- Trial firm Simon Greenstone Panatier, PC, widely known for its successful toxic tort, mass torts and catastrophic injury plaintiffs representation, has been selected as Attorney at Law Magazine Dallas' inaugural Law Firm of the Year.

Key Points: 
  • DALLAS, Oct. 26, 2023 /PRNewswire/ -- Trial firm Simon Greenstone Panatier, PC , widely known for its successful toxic tort, mass torts and catastrophic injury plaintiffs representation, has been selected as Attorney at Law Magazine Dallas' inaugural Law Firm of the Year.
  • According to Attorney at Law Magazine, "Simon Greenstone Panatier is a top-tier firm that checks all the boxes," adding that the firm's mix of practice areas along with firm diversity, its compelling history and national reach were key factors in the selection.
  • Equally dedicated to giving back to the community, each year the firm presents the Simon Greenstone Panatier, PC, Scholarship.
  • The firm also supports the North Texas Food Bank, the Dallas Volunteer Attorney's Program and various mesothelioma and cancer charities.

Elevar Therapeutics Names Brian Cunningham Vice President of Sales and Kenneth Rankin Vice President of Market Access, Strengthening Commercial Leadership in Buildup to Launch

Retrieved on: 
Monday, October 23, 2023
FDA, HCC, Greater China, PDUFA, Food, Strategic planning, Incyte, Kutztown University of Pennsylvania, University, Mesothelioma, Bowling Green State University, Regulation of tobacco by the U.S. Food and Drug Administration, Pfizer, Array BioPharma, Cunningham, Business administration, Hepatocellular carcinoma, Football, Therapy, Master of Business Administration, Patient, Communication, Pharmaceutical industry, Management

"The additions of Brian Cunningham and Kenneth Rankin come at an important and exciting time for Elevar, as we position the company for a potential commercial launch in the coming year,” said Elevar Chief Commercial Officer Paul Friel.

Key Points: 
  • "The additions of Brian Cunningham and Kenneth Rankin come at an important and exciting time for Elevar, as we position the company for a potential commercial launch in the coming year,” said Elevar Chief Commercial Officer Paul Friel.
  • “Both possess a wealth of sales and management acumen, and a great understanding of the road ahead for our company.
  • Cunningham joins Elevar from global oncology company Novocure, where he served as the national sales and operations lead for its Central Nervous System Cancers Franchise.
  • He was previously vice president of sales for rare commercial services at Dohmen Life Science Services, and director of Eisai Inc.’s government payer team.

Possible Third J&J Bankruptcy Attempt Amplifies Concerns over Corporate Abuse of Courts

Retrieved on: 
Tuesday, October 24, 2023
MDL, Ovarian cancer, Bankruptcy, Congress, United States Court of Appeals for the Third Circuit, AAA, Texas two-step bankruptcy, Seventh Amendment, J&J, United States bankruptcy court, Asbestos, Mesothelioma, Woman, Johnson & Johnson, Talc, Tobacco

"J&J's corporate leadership seems determined to keep pushing this strategy, and as advocates for these women we will continue to push back."

Key Points: 
  • "J&J's corporate leadership seems determined to keep pushing this strategy, and as advocates for these women we will continue to push back."
  • During the past year, the U.S. Bankruptcy Court in New Jersey and the Third U.S.
  • Circuit Court of Appeals has ruled J&J's ploy does not meet the standards for a good faith bankruptcy, in large part because the multibillion-dollar company is not in "financial distress."
  • Attorneys for the plaintiffs believe that under bankruptcy laws those victims would receive far less compensation than through civil trials or settlement negotiations outside of the bankruptcy system.

Opdivo (nivolumab) in Combination with Cisplatin-Based Chemotherapy Followed by Opdivo Demonstrates Significant Survival Benefits for Cisplatin-Eligible Patients with Unresectable or Metastatic Urothelial Carcinoma in Phase 3 CheckMate -901 Trial

Retrieved on: 
Tuesday, October 17, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Congress, HIV disease progression rates, Confidence interval, Bristol Myers Squibb, NYSE, Death, Abstract, Mesothelioma, Disclosure, Cancer, ORR, Risk, Safety, Lung cancer, Survival, European Society for Medical Oncology, ESMO, Doctor of Philosophy, Carcinoma, Immunotherapy, Checkmate, Clinical Genitourinary Cancer, EDT, PFS, Neoplasm, Progression-free survival, BMY, Netherlands Cancer Institute, Patient, CR, Pharmaceutical industry, Platinum, Nivolumab

At the 12- and 24-month landmark analyses, patients treated with upfront Opdivo plus chemotherapy experienced OS rates of 70.2% and 46.9%, respectively, compared to 62.7% and 40.7% with chemotherapy.

Key Points: 
  • At the 12- and 24-month landmark analyses, patients treated with upfront Opdivo plus chemotherapy experienced OS rates of 70.2% and 46.9%, respectively, compared to 62.7% and 40.7% with chemotherapy.
  • The landmark 12- and 24-month PFS rates were 34.2% and 23.5%, compared to 21.8% and 9.6% with chemotherapy.
  • The combination of Opdivo with cisplatin-based chemotherapy had a tolerable safety profile consistent with the known safety profiles of the individual components of the regimen.
  • “In patients with metastatic urothelial carcinoma, we often see poor durability of responses with chemotherapy alone in the first-line treatment setting.